Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a wearable sensor improve blood sugar control in hospitals?

NCT ID NCT07796802

Disease control Sponsor: Steno Diabetes Center Copenhagen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

This trial tests whether continuous glucose monitoring (CGM) can improve blood sugar control and reduce complications in hospitalized adults with type 2 diabetes, compared to standard finger-prick testing. Participants are randomly assigned to either CGM with a sensor-guided insulin algorithm or standard care with point-of-care glucose tests. The study tracks time in range, hospital complications, length of stay, and readmission rates to see if the wearable device offers real benefits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Continuous glucose monitoring (CGM) with the Dexcom G7 device, used to guide insulin dosing in the hospital.
What this could lead to
If it works, continuous glucose monitoring could become the standard way to manage blood sugar in hospitalized diabetes patients, potentially reducing complications and shortening hospital stays.
What could go wrong
The trial is relatively small and early, and the device may not prove better than standard care in all patients. There is also a small risk of skin irritation from the sensor.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 314 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2027

An estimate. Start dates often move.

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Type 2 diabetes defined as treatment with at least one glucose-lowering therapy prior to inclusion AND * age ≥ 18 years old AND * willingness and ability to comply with the trial protocol AND * ability to communicate (in Danish or English) with the trial personnel AND * an expected length of hospital stay for at least two days after enrolment. Exclusion Criteria: * Known hypersensitivity to the band-aid of the CGM Dexcom G7 sensor OR * Pregnancy OR * Patients admitted with diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) OR * Concomitant treatment with hydroxyurea (CGM contraindication) OR * Treatment with enteral or parenteral nutrition.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Continuous glucose monitoring system are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Continuous glucose monitoring system Diabetes Inpatient

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.